Mizuho Securities Upgrades Myriad Genetics (MYGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Stephens Resumes Myriad Genetics (MYGN) at Overweight
May 9, 2013 7:53 AM EDTStephens resumed coverage on Myriad Genetics (NASDAQ: MYGN) with an Overweight rating and a price target of $38.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more... More
Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 6c
May 7, 2013 4:29 PM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.46, $0.06 better than the analyst estimate of $0.40. Revenue for the quarter came in at $156.5 million versus the consensus estimate of $148.25 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.... More
